RecruitingPhase 2NCT04100174
Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Enrollment
150 participants
Start Date
Jul 1, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL
Eligibility
Sex: MALE
Inclusion Criteria5
- Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
- ECOG 0-1
- Charlson Comorbidity Index ≤ 4
- Imaging visible disease encompassing \< 50% of the prostate gland and consistent with biopsy findings.
- Exclusion - none
Interventions
RADIATIONfocal brachytherapy boost to SBRT
As above
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04100174
Related Trials
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
NCT070271241 location
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location